Spots Global Cancer Trial Database for metastatic gastroesophageal junction adenocarcinoma

Every month we try and update this database with for metastatic gastroesophageal junction adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	NCT05555251	HER2-positive B... HER2-positive G... HER2-positive M... Metastatic Gast... Metastatic Gast...	BI-1607 BI-1607 Trastuzumab	18 Years -	BioInvent International AB
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines	NCT04535401	Advanced Colore... Advanced Digest... Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Colo... Metastatic Dige... Metastatic Gast... Metastatic Gast... Stage III Color... Stage IV Colore...	Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Fluorouracil Irinotecan Hydr... Leucovorin Calc...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	NCT04704661	Advanced Breast... Advanced Colon ... Advanced Colore... Advanced Endome... Advanced Gastri... Advanced Gastro... Advanced Malign... Advanced Saliva... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... HER2-Positive B... Malignant Hepat... Metastatic Brea... Metastatic Gast... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Colon... Stage III Color... Stage III Major... Stage III Uteri... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Uter... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Colon ... Stage IV Colore... Stage IV Major ... Stage IV Uterin... Stage IVA Colon... Stage IVA Color... Stage IVA Major... Stage IVA Uteri... Stage IVB Colon... Stage IVB Color... Stage IVB Major... Stage IVB Uteri... Stage IVC Colon... Stage IVC Color... Stage IVC Major... Unresectable Co... Unresectable Ga... Unresectable Ma...	Ceralasertib Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines	NCT04535401	Advanced Colore... Advanced Digest... Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Colo... Metastatic Dige... Metastatic Gast... Metastatic Gast... Stage III Color... Stage IV Colore...	Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Fluorouracil Irinotecan Hydr... Leucovorin Calc...	18 Years -	National Cancer Institute (NCI)
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	NCT06203600	Advanced Esopha... Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Ga... Unresectable Ga...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Nivolumab Paclitaxel Questionnaire A... Ramucirumab	18 Years -	National Cancer Institute (NCI)
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma	NCT03395847	Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Gastroesophagea... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Unresectable Ga...	Pembrolizumab	18 Years -	M.D. Anderson Cancer Center
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca	NCT04921904	Metastatic Esop... Metastatic Gast...	Abemaciclib Ramucirumab	18 Years -	Baylor Research Institute
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer	NCT06251973	Metastatic Esop... Advanced Unrese... Metastatic Gast... Metastatic Gast... Metastatic Esop... Metastatic Esop... Metastatic Gast... Metastatic Gast... Unresectable Es... Unresectable Es... Unresectable Ga... Unresectable Ga... Unresectable Ga...	AgenT-797 Botensilimab Balstilimab Ramucirumab Paclitaxel	18 Years -	Memorial Sloan Kettering Cancer Center
Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer	NCT05342389	Metastatic Gast... Metastatic Gast...	Camrelizumab Apatinib Mesyla...	18 Years - 75 Years	Sixth Affiliated Hospital, Sun Yat-sen University
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	NCT05733000	Advanced Biliar... Advanced Colore... Advanced Gastro... Advanced Lung A... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Urothe... Clinical Stage ... Clinical Stage ... Metastatic Bili... Metastatic Colo... Metastatic Gast... Metastatic Lung... Metastatic Ovar... Metastatic Panc... Metastatic Urot... Refractory Bili... Refractory Colo... Refractory Gast... Refractory Lung... Refractory Ovar... Refractory Panc... Refractory Urot... Stage II Pancre... Stage III Color... Stage III Lung ... Stage III Ovari... Stage III Pancr... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Pancre...	Biospecimen Col... Computed Tomogr... Devimistat Fluorouracil Gemcitabine Hyd... Hydroxychloroqu... Magnetic Resona...	18 Years -	Northwestern University
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer	NCT04511039	Advanced Malign... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Colo... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color...	Trifluridine an... Talazoparib Tos...	18 Years -	Roswell Park Cancer Institute
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines	NCT04535401	Advanced Colore... Advanced Digest... Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Colo... Metastatic Dige... Metastatic Gast... Metastatic Gast... Stage III Color... Stage IV Colore...	Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Fluorouracil Irinotecan Hydr... Leucovorin Calc...	18 Years -	National Cancer Institute (NCI)
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	NCT05555251	HER2-positive B... HER2-positive G... HER2-positive M... Metastatic Gast... Metastatic Gast...	BI-1607 BI-1607 Trastuzumab	18 Years -	BioInvent International AB
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers	NCT04221893	Stage IV Esopha... Stage IV Esopha... Stage IV Gastri... Stage IV Adenoc... Stage IVA Esoph... Stage IVA Esoph... Stage IVA Gastr... Stage IVA Adeno... Stage IVB Esoph... Stage IVB Esoph... Stage IVB Gastr... Stage IVB Gastr... Metastatic Anal... Metastatic Colo... Metastatic Esop... Metastatic Gast... Metastatic Gast... Metastatic Hepa... Metastatic Mali... Metastatic Smal... Pancreatobiliar... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage IV Anal C... Stage IV Colore... Stage IV Hepato... Stage IVA Color... Stage IVA Hepat... Stage IVB Color... Stage IVB Hepat... Stage IVC Color...	Radiation Thera...	18 Years -	University of California, San Francisco
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	NCT03641313	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Unresectable Ga... Unresectable Ga...	Berzosertib Computed Tomogr... Endoscopic Biop... Irinotecan Magnetic Resona...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	NCT05041153	Advanced Gastri... Advanced Gastro... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Ga... Unresectable Ga...	Lenvatinib Pembrolizumab	18 Years -	M.D. Anderson Cancer Center
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery	NCT03008278	Metastatic Esop... Metastatic Gast... Metastatic Gast... Recurrent Esoph... Recurrent Gastr... Recurrent Gastr... Stage III Esoph... Stage III Gastr... Stage IV Esopha... Stage IV Gastri... Unresectable Es... Unresectable Ga... Unresectable Ga...	Olaparib Ramucirumab	18 Years -	National Cancer Institute (NCI)
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca	NCT04921904	Metastatic Esop... Metastatic Gast...	Abemaciclib Ramucirumab	18 Years -	Baylor Research Institute
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer	NCT01142388	Metastatic Esop... Metastatic Esop... Metastatic Gast... Recurrent Esoph... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IV Esopha...	Cixutumumab Laboratory Biom... Paclitaxel Pharmacological...	18 Years -	National Cancer Institute (NCI)
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca	NCT04921904	Metastatic Esop... Metastatic Gast...	Abemaciclib Ramucirumab	18 Years -	Baylor Research Institute
MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C	NCT02391038	Advanced Gastro... Gastroesophagea... Recurrent Gastr... Recurrent Gastr... Metastatic Gast... Metastatic Gast... Recurrent Gastr...	MLN0264	18 Years -	Takeda
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer	NCT04511039	Advanced Malign... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Colo... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color...	Trifluridine an... Talazoparib Tos...	18 Years -	Roswell Park Cancer Institute
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer	NCT04220827	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Peritoneal Carc... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant...	Paclitaxel	18 Years -	M.D. Anderson Cancer Center
Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer	NCT05342389	Metastatic Gast... Metastatic Gast...	Camrelizumab Apatinib Mesyla...	18 Years - 75 Years	Sixth Affiliated Hospital, Sun Yat-sen University
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer	NCT06329973	Metastatic Gast...	Fruquintinib in...	18 Years - 75 Years	Henan Cancer Hospital
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma	NCT05651594	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Esop... Metastatic Gast... Unresectable Es... Unresectable Ga...	Biopsy Biospecimen Col... Computed Tomogr... Fluorouracil Leucovorin Oxaliplatin Pembrolizumab Propranolol Hyd... Questionnaire A...	18 Years -	Roswell Park Cancer Institute
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer	NCT06329973	Metastatic Gast...	Fruquintinib in...	18 Years - 75 Years	Henan Cancer Hospital
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers	NCT04460937	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Distal Esophagu... Gastric Cardia ... Metastatic Esop... Metastatic Esop... Metastatic Gast... Metastatic Mali... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Unresectable Es... Unresectable Es... Unresectable Es... Unresectable Ga...	Adavosertib Radiation Thera...	18 Years -	National Cancer Institute (NCI)
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer	NCT03918499	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Recurrent Gastr... Recurrent Gastr...	Cyclophosphamid... Cytokine-based ... Pembrolizumab	18 Years -	City of Hope Medical Center
MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C	NCT02391038	Advanced Gastro... Gastroesophagea... Recurrent Gastr... Recurrent Gastr... Metastatic Gast... Metastatic Gast... Recurrent Gastr...	MLN0264	18 Years -	Takeda
MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	NCT03739801	Locally Advance... Metastatic Gast... Metastatic Unre... Unresectable Ga... Gastric Adenoca... Gastroesophagea...	Liposomal Irino... Quality-of-Life... Questionnaire A... Ramucirumab	18 Years -	University of Southern California
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors	NCT06364410	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Mali... Unresectable Ga... Unresectable Ga... Unresectable Ma...	Azenosertib Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors	NCT06364410	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Mali... Unresectable Ga... Unresectable Ga... Unresectable Ma...	Azenosertib Biopsy Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca	NCT04921904	Metastatic Esop... Metastatic Gast...	Abemaciclib Ramucirumab	18 Years -	Baylor Research Institute
MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	NCT03739801	Locally Advance... Metastatic Gast... Metastatic Unre... Unresectable Ga... Gastric Adenoca... Gastroesophagea...	Liposomal Irino... Quality-of-Life... Questionnaire A... Ramucirumab	18 Years -	University of Southern California
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	NCT04660760	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant... Postneoadjuvant...	Paclitaxel Quality-of-Life... Ramucirumab Trifluridine an...	18 Years -	Academic and Community Cancer Research United

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: